Intranasal Technology, Inc. Licenses Aegis Therapeutics' Intravail
`Drug Delivery Technology
`
`BIOWIRE2K
`
`April 13, 2005 12:40 PM Eastern Daylight Time
`
`SAN DIEGO & LEXINGTON, Ky.--(BUSINESS WIRE)--April 13, 2005--Aegis
`Therapeutics ("Aegis") and Intranasal Technology, Inc. ("ITI") today announced that they
`have entered into a collaborative agreement to apply Aegis' patented Intravail(TM) drug
`delivery technology to a therapeutic to be developed by ITI.
`
`"ITI has an impressive product pipeline and unique manufacturing process currently focused on the nasal
`administration of small molecule therapeutics," said Edward T. Maggio, Ph.D., Aegis' President and Chief Executive
`Officer. "The application of Aegis' non-invasive drug delivery technology provides ITI a unique benefit as it develops
`exciting new therapeutic products that hold advantages for both patients and healthcare professionals."
`
`Aegis' Intravail(TM) absorption enhancement agents are mild and non-irritating to mucosal membranes, providing
`exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection. Via
`the intranasal, ocular and other mucosal membrane administration routes, these agents help deliver potent peptide,
`protein, and large molecule drugs that currently can be delivered only by injection.
`
`"The Intravail(TM) drug delivery technology for protein and peptide therapeutics fits nicely into our strategy of
`developing unparalleled product offerings in the nasal drug delivery arena," said John C. Carlisle, ITI President and
`Chief Executive Officer. "Intravail's remarkable bioavailability and safety data, along with ITI's fully integrated product
`development and manufacturing capabilities, will allow us to accelerate our efforts to bring a product to market quickly
`that improves safety, efficacy and convenience for patients, their caregivers and physicians."
`
`ITI is working on the development of a number of new drug formulations and technologies for nasal delivery, including
`sedatives, anticonvulsants, nerve agent antidotes, medications for migraine headache, and panic disorder. ITI has
`performed 18 human trials, and a patent has been issued for the lorazepam nasal compound and related delivery
`technology. Patents also have been filed for other benzodiazepines and opioids.
`
`Nasal drug delivery has numerous advantages benefits for patients and healthcare professionals, including rapid onset
`of action, non-invasive and virtually pain-free delivery, and the elimination of needles and biohazardous wastes. In
`addition, nasally delivered drugs have the potential for direct transfer across the blood brain barrier, which could
`
`/
`
`Neurelis - EX.2028
`Aquestive Therapeutics, Inc. v. Neurelis, Inc. - IPR2019-00451
`
`

`

`improve the efficacy of many central nervous system products.
`
`About Aegis Therapeutics
`
`Aegis Therapeutics Inc. is a specialty pharmaceutical company formed to commercialize advanced patented drug
`delivery technologies that enable the non-invasive delivery of a broad range of protein, peptide and non-peptide
`macromolecular therapeutics. Aegis' Intravail(TM) absorption agents have numerous competitive advantages, including
`rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier with no or
`minimal irritation, avoidance of gastric hydrolysis in the stomach and "first pass effect" elimination by the liver that can
`accompany oral administration, greater patient convenience and compliance, elimination of needlestick injuries and
`associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, ease of
`formulation and compatibility with routine homogeneous formulation and dispensing manufacturing processes for ease
`of scale-up and production. For more information about Aegis, please visit www.aegisthera.com.
`
`About ITI
`
`Intranasal Technology, Inc. (ITI) is a specialty pharmaceutical company that develops rapid onset prescription drug
`formulations and innovative nasal drug delivery products to address unmet clinical needs. ITI develops new and
`differentiated proprietary products by expertly combining its formulation research expertise, clinical evaluation
`capability, delivery systems technology, and the aseptic manufacturing and packaging of nasal spray drug products.
`The Company controls all key aspects of the development cycle to ensure that products get to market quickly and
`efficiently. ITI currently is focused on nasally delivered analgesics and anxiolytics, and is seeking partners to market
`existing compounds and newly acquired compounds that offer significant clinical benefits and market potential. For
`more information please visit http://www.intranasal.com.
`
`Contacts
`Aegis Therapeutics
`Edward T.Maggio, Ph.D., 858.618.1400 Ext. 101
`Fax: 858.618.1441
`emaggio@aegisthera.com
`or
`ITI
`John C. Carlisle, 859-252-5050
`Fax: 859-252-7280
`jcarlisle@intranasal.com
`
`/
`
`Neurelis - EX.2028
`Aquestive Therapeutics, Inc. v. Neurelis, Inc. - IPR2019-00451
`
`